Is Atai Beckley N.V (ATAI) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Atai Beckley N.V (ATAI) using a discounted cash flow (DCF) model and long-term earnings assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ATAI a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ATAI trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

ATAI

Atai Beckley N.V

$3.57

0.01

(0.28%)

Exchange:
Market Cap:	673.391M
Shares Outstanding:	152.57M

Overview

Earnings

Financials

Valuation

Chart

About The Company

Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

Click to read more…